CO2 Laser Therapy for Genitourinary Syndrome of Menopause in Women with Breast Cancer: A Randomized, Sham-Controlled Trial
Cancers · 06.04.2025 · 17 (7) · 1241
DOI: 10.3390/cancers17071241 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 06.04.2025. Verfasst von Sireen Jaber und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Hadassah-Hebrew University Medical Center, Jerusalem 9765422, Israel. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Israel Cancer Association.
Abstract (Originalsprache)
Objectives
We aimed to study the efficacy of fractional CO2 laser for genitourinary syndrome of menopause (GSM) symptoms in breast cancer (BC) survivors through a randomized, sham-controlled study, followed by an open-phase study assessing the impact of additional treatments.
Methods
BC survivors with GSM were randomized to receive either three sessions of intravaginal CO2 laser or sham treatment every 3–4 weeks. The laser’s energy was 45–60 mJ/pixel. Outcomes were compared one month following the last session. Participants initially receiving laser treatment were offered three more sessions, while those receiving sham had six laser sessions in an open-label study.
Results
Thirty-four BC survivors were randomized to laser (n = 19) or sham (n = 15) treatments. Dyspareunia and intercourse dryness scores improved in both groups one month post-treatment, without a significant advantage of laser over sham. The laser treatment resulted in a reduction in daily dryness (−1.30 ± 0.55, p = 0.017), an increase in vaginal hydration (3.24 ± 1.13, p = 0.004), and an increase in Vaginal Health Index (VHI) (2.26 ± 0.50, p < 0.001). Most participants (18/19 and 9/15, respectively) opted to continue laser treatments after unblinding, resulting in 27 patients receiving six laser treatments. Increasing the number of laser treatments was associated with a constant improvement in Visual Analogue Score (VAS) scores for dyspareunia, intercourse dryness, daily dryness, burning, discomfort, itch, and average VAS, as well as pH, VHI, and hydration.
Conclusions
Three fractional CO2 laser treatments for BC survivors reduced daily dryness but did not improve dyspareunia and sexual dryness when compared to sham in this randomized trial. Increasing the number of treatment sessions seemed to improve outcomes; however, it remained clinically insufficient, even after six treatments.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Hadassah-Hebrew University Medical Center, Jerusalem 9765422, Israel.
- The Department of Gynecologic Oncology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9190500, Israel.
- Lady Davis Institute for Cancer Research, Jewish General Hospital, McGill University, Montreal, QC H3A 0G4, Canada.
- Clalit Health Organization, Jerusalem 9780214, Israel.
- Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9190500, Israel.
ORCID-Profile: Gabriel Levin, Ahinoam Lev-Sagie
Förderung
- Israel Cancer Association
Zitieren
APA
Jaber, S., Levin, G., Ram-Weiner, M., & Lev-Sagie, A. (2025). CO2 Laser Therapy for Genitourinary Syndrome of Menopause in Women with Breast Cancer: A Randomized, Sham-Controlled Trial. Cancers, 17(7), 1241. https://doi.org/10.3390/cancers17071241
Vancouver
Jaber S, Levin G, Ram-Weiner M, Lev-Sagie A. CO2 Laser Therapy for Genitourinary Syndrome of Menopause in Women with Breast Cancer: A Randomized, Sham-Controlled Trial. Cancers. 2025;17(7):1241. doi:10.3390/cancers17071241
BibTeX
@article{Jaber2025,
author = {Jaber, Sireen and Levin, Gabriel and Ram-Weiner, Maya and Lev-Sagie, Ahinoam},
title = {CO2 Laser Therapy for Genitourinary Syndrome of Menopause in Women with Breast Cancer: A Randomized, Sham-Controlled Trial},
journal = {Cancers},
year = {2025},
volume = {17},
number = {7},
pages = {1241},
doi = {10.3390/cancers17071241}
}
EUVIMED